{"id":"NCT02996682","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis","officialTitle":"A Multicenter, Randomized, Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Decompensated Cirrhosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-26","primaryCompletion":"2018-02-13","completion":"2018-05-08","firstPosted":"2016-12-19","resultsPosted":"2019-02-26","lastUpdate":"2019-02-26"},"enrollment":102,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["Epclusa®"]},{"type":"DRUG","name":"RBV","otherNames":["Rebetol®"]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"},{"label":"SOF/VEL + RBV","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection and decompensated cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL","deltaMin":92.2,"sd":null},{"arm":"SOF/VEL + RBV","deltaMin":92.2,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":33,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":51},"commonTop":["Anaemia","Nasopharyngitis","Diarrhoea","Oedema peripheral","Headache"]}}